Madrigal & Ribo Hit Key Milestone, Advance Novel MASH Therapy to IND-Enabling Studies
MDGL sits 81% above its 52-week low of $284.023.
Summary
Madrigal Pharmaceuticals and Ribo have achieved the first candidate drug nomination milestone in their siRNA partnership for Metabolic dysfunction-associated steatohepatitis (MASH). This progress triggers the immediate initiation of IND-enabling studies, moving a novel therapeutic candidate closer to clinical trials. This development expands Madrigal's pipeline in the MASH space, building on its established market presence with Rezdiffra, which recently reported strong Q1 sales and positive Phase 3 data. The milestone demonstrates the company's commitment to diversifying its MASH treatment portfolio and leveraging cutting-edge RNA therapeutics.
At the time of this announcement, MDGL was trading at $514.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9B. The 52-week trading range was $284.02 to $615.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.